269 results about "Medical biology" patented technology

The invention relates to the technical field of medical biology, and specifically discloses a novel coronavirus (SARS-COV-2) spike protein binding molecule and applications thereof. The binding molecule can specifically bind the spike protein of SARS-COV-2 and includes at least one immunoglobulin single variable structural domain. The provided binding molecule can specifically bind the SARS-COV-2-Spike protein and effectively block the binding of the SARS-COV-2-Spike protein and human cell ACE2 receptors, so that the infection process of the SARS-COV-2 on cells can be further blocked, and theinfection and amplification of the SARS-COV-2 can be inhibited.

The invention belongs to the field of medical biology engineering, and particularly relates to a method for effectively multiplying gamma delta T cells by stimulating peripheral blood in vitro and application of the method. The method comprises the step of using feeder cells, an OKT3 (ornithine ketoacid transaminase) antibody, interleukin-2 and zoledronic acid. The feeder cells are formed by specifically inserting CD64, CD86 and CD137L genes in a target site of a genome of the feeder cells. After the zoledronic acid and the nterleukin-2 are used for increasing the proportion of the gamma delta T cells of the peripheral blood, protein products of genes, the OKT3 antibody and the interleukin-2 act in a combined manner, and the gamma delta T cells can be stimulated so that a large amount of gamma delta T cells can be multiplied. The multiplied gamma delta T cells can be used for killing tumor cells which are pretreated by the zoledronic acid, or the tumor cells can be directly killed by modifying and expressing chimeric antigen receptors (CAR) via a genetic engineering means. The gamma delta T cells which are obtained by the method have complete anti-tumor cytotoxicity, and can kill solid tumor cells and non-solid tumor cells.

The invention belongs to the field of medical biology, and particularly relates to a method for extracting a konjac polypeptide extract from konjac flying powder, the konjac polypeptide extract obtained by the method and an application of the konjac polypeptide extract. In order to increase the content of konjac polypeptide in the konjac polypeptide extract, the optimized extraction technology provided by the invention adopts a complex enzyme to perform enzymolysis on the protein extraction liquid of the konjac flying powder; in the finally obtained konjac polypeptide extract, the content of konjac polypeptide is as high as 85-97%, and the molecular weight of the konjac polypeptide is 350-3500Da. Moreover, the invention also provides an application of the konjac polypeptide extract in preparing a medicine for treating diabetes and diabetic complications as well as a hypoglycemic medicinal composition containing the konjac polypeptide extract. In a word, the konjac polypeptide extract and the medicinal composition thereof provided by the invention have good prospect in medicine.

The invention relates to a digital image based rapid solving method of circle parameters, which comprises the steps of: 1, acquiring an image of a measured object by using a digital image sensor to establish a plane coordinate system; 2, carrying out Histogram analysis on the image to determine a threshold suitable for separating a boundary of a circle to be measured; and carrying out region segmentation on the acquired image to set a square region including the circle to be measured; 3, selecting an inner point of the circle according to the threshold determined in the step 2, and searching from the point to obtain a point at the edge of the circle to be measured in the image; 4, setting a dynamic step length S, obtaining a point set sequence at the edge of the circle to be measured according to an edge point searching rule in the step 3; and 5, solving coordinates of the center of the circle and diameter parameters of the circle. The invention can be applied to the geometric parameter measurement of a circular pat or instrument in the fields of industrial detection, medical biology and the like, better solves the contradiction between speed and effect during solving the circle parameters in the digital image, and has high practical application value.

The invention discloses a method for detecting nucleic acid by a colloidal gold chromatography technology and a reagent kit, and belongs to the technical field of medical biology. A universal test paper strip for nucleic acid detection is provided; colloidal gold particles are marked on a universal probe 1, and then, the universal probe is fixed on a glass cellulose membrane; the probe sequence is designed into a universal sequence; the test paper strip is fixed on a PVC (polyvinyl chloride) bottom plate; a sample pad, glass fiber, an NC membrane and water absorption paper are in sequential arrangement from the left side to the right side, wherein a T line (detection line) and a C line (quality control line) are arranged on the NC membrane; antibodies to labels b cover the detection line; antibodies to labels a cover the quality control line; the specificity probe A series and the specificity B series successfully combine a gold mark probe and nucleic acid amplification fragments in series; the specificity detection of nucleic acid amplification fragments is realized. The method has the advantages that the technical requirement on the experiment personnel is low; the required detection time is short; special instrument equipment is not needed; the popularization to basic levels and remote rural area medical institutions is easy.

The invention discloses a dynamic speckle measurement method for the particle size and concentration change of turbid medium. The invention adopts the principle that when laser irradiates on turbid medium solution with dynamic change, dynamic speckles are formed in a forward scattering field and a backward scattering field, and the speckle size and contrast value of a dynamic speckle picture is in direct proportion with the particle size in the turbid media and in inverse proportion with concentration. Therefore, the particle size and concentration change in the turbid medium can be dynamically monitored in a real time mode by calculating the change of speckle size and contrast value of a dynamic speckle picture sequence. The method is a non-invasive type detection method, has the characteristics of simple operation and wide application range, and can be widely applied in the fields of medical biology, atmospheric environmental monitoring, underwater exploration, and the like.

The invention discloses a detection method which is used for making a filtering membrane transparent in the process of performing inspection and detection by using a membrane separation technology in fields of medical science, biology, environtology and the like and is applied to membrane separation and membrane transparent liquid. According to the detection method applied to the membrane separation, the membrane transparent liquid is added into the filtering membrane in the process of detecting ingredients entrapped by the filtering membrane, so that the filtering membrane is in the transparent state; the filtering membrane has the performance of a transparent material, and the prepared filtering membrane is in the nontransparent or semitransparent state; and an error of the refractive index of the membrane transparent liquid and the refractive index of the material of the filtering membrane is within +/-10 percent. By the membrane transparent liquid, the filtering membrane becomes transparent, so that substances which are adhered to the filtering membrane can be observed and counted directly.

Materials and manufacturing techniques to produce test strips in high volume at low-cost for the measurement of gas in various industries and environments are disclosed. The test strip is generally comprised of a substrate, at least one electrical connection, at least one sensing chemistry and at least one additional layer. The test strip may provide a quantitative and/or a qualitative read out. A method for collecting and analyzing data to monitor and manage patients with chronic respiratory disease is disclosed. Implementations include software applications, connected medical devices, web servers and electronic catalogs. A method for identifying treatment trends from a population combining medical, biological and environmental data is disclosed. A method for proactively alerting and patients, caregivers and medical providers to trends in health by using the implementations of the invention are disclosed.

The invention relates to the medical biology detection technical field and discloses a method for quickly detecting DNA methylation. Aiming at the disadvantages of the prior method, the method provided by the invention improves the following three aspects: 1. catalyst TAC and guanidine hydrochloride are added to accelerate the modification reaction; 2. short-time high-temperature melting is performed during the modification reaction for times so as to fully expose basic groups to transform cytimidine which is not made from methylation modification to sulfonated uracil; 3. aiming at fussy dialysis desalination steps after the modification, when a modified DNA product is purified, the modified DNA product is combined into a glass fiber membrane or pellosil or other pillars for washing desalination, then is treated by sulfated reagent and eluted, thereby obtaining a methylated PCR template which can be directly used for PCR augmentation and greatly saves desalination time. The method has low cost, short detection time and good repetitiveness.

The invention belongs to the field of medical biology, and specifically provides a designing and preparing method of a class of effective signal transduction inhibition compounds for signal transducerand activator of transcription type3 (STAT3), and applications of the effective signal transduction inhibition compounds mainly in clinical treatment of breast cancer. According to the present invention, a variety of breast cancer cell lines have the abnormal intracellular STAT3 signaling system regulation mechanisms, and the compounds of the present invention can significantly inhibit the signaltransduction of STAT3 so as to provide the potential important significance in the clinical treatment and research of breast cancer.

The invention relates to the technical field of medical detection and discloses a creatinine detection kit. The creatinine detection kit provided by the invention comprises 2,4,6-trinitrophenol, a buffer solution with the pH ranging from 12.5 to 13.5 and a mixture of triton X-100 and dimethyl sulfoxide. The mixture of triton X-100 and dimethyl sulfoxide can surround the molecules of 2,4,6-trinitrophenol so as to slow down the fast contact of 2,4,6-trinitrophenol with NaOH in a buffer system with the pH ranging from 12.5 to 13.5, so that the stability of reagents is increased and the accuracy of a creatinine detection result is guaranteed. Tests show that the kit disclosed by the invention has the advantages of good stability, long retention period, high creatinine detection accuracy, goodcreatinine detection precision and wide linear range. The kit disclosed by the invention has a wide applicable scope, is convenient for popularization and use, and can be applied to the determinationof creatinine content in serum in hospitals at all levels, departments of health and epidemic prevention and research and development institutes of medical biology.

The invention belongs to the field of medical biology, and particularly relates to a dual-target CAR vector combining EpCAM and MSLN single-chain antibodies, a construction method of the dual-target CAR vector and an application of the dual-target CAR vector in breast cancer. The dual-target CAR-T therapeutic vector is combined with the EpCAM single chain antibody and the MSLN single chain antibody, specifically CD8leader-EpCAM scFv-CD8 alpha-CD28-CD137-IRES-CD8leader-MSLN scFv-CD8alpha-CD3zeta. The CAR-T cell (Chimeric Antigen Receptor T-Cell) containing the therapeutic vector is obtained byviral infection, and by expressing the CAR structure, targeted identification and killing of breast cancer cells with high expression of EpCAM and MSLN tumor-associated antigens can be achieved.

The invention belongs to the field of medical biology, and particularly relates to a production method for recombining scorpion toxin protein AGAP. The method comprises the following steps: firstly, obtaining SUMO-AGAP fusion genes with His6 labels by using overlapping PCR technology; secondly, constructing a recombinant expression vector containing the SUMO-AGAP fusion genes; thirdly, transferring the constructed expression vector to a host cell to express; and finally, cracking the cell by using a physical method or a chemical agent, extracting recombinant fusion protein and His purified fusion protein to obtain pure SUMO-AGAP fusion protein, carrying out enzyme cutting reaction, releasing AGAP, and further purifying the fusion protein to obtain the purified AGAP protein. The method greatly improves the yield, saves the cost, and is simple and convenient to operate; and the AGAP produced by the method has broad biologic activity, can restrain the proliferation of various tumor cells, and simultaneously has analgesia effect.

The invention discloses a monoclonal antibody hybrid tumor cell strain KGH-R1 of broad spectrum anti-human p21Ras protein and a monoclonal antibody, belongs to the field of medical biology, and in particular relates to the monoclonal antibody hybrid tumor cell strain KGH-R1 of broad spectrum anti-human p21Ras protein and the monoclonal antibody. The hybrid tumor is preserved in a China center for type culture collection in September 23rd 2011, and has the preservation number of CCTCCNO: C201197. A mouse monoclonal antibody which has synchronous antagonism to three types of active Ras protein is finally obtained; and the monoclonal antibody which aims at a p21Ras protein target can be used for protein clinical test, can also construct an intracellular antibody, has an active tumor prevention function by inhibiting tissue vicious transformation through resisting overexpressed Ras protein, and has an active target antitumous effect on the tumor which corresponds to the overexpressed Ras protein.

The invention provides application of LncRNA (long non-coding RNA) and a medicine using the same, and relates to the technical field of medical biology. The LncRNA provided by the invention has the nucleotide sequence shown as SEQ ID NO.1, and experiments find that the expression of the LncRNA is significantly decreased in cardiomyocytes suffering from cell death and heart tissues and the LncRNA has a protective effect on myocardial infarction and myocardial fibrosis, so that through overexpression of the LncRNA, the purposes of preventing and/or treating heart diseases can be achieved. The invention further provides the medicine comprising the LncRNA. The medicine can achieve the purposes of preventing and/or treating the heart diseases through the overexpression of the LncRNA; meanwhile,the medicine is obvious in therapeutic effect, wide in application range and friendly to using environment.

The invention belongs to the technology of medical biology and relates to organ preservative fluid and the method for making same. The procedure to prepare 1000ml of the fluid is as follows, tetrahydrobiopterin 1.57mg and diazoxide 6.92mg are dissolved in 1ml of dimethyl sulfoxide to act as mother liquid, CaCl2 of 0.1mol/L is prepared for backup, double distilled water 800ml is charged in a container of 1000ml, KCl 1.12g, MgCl2 2.64g, manna sugar 10.93g, histidine 4.63g, glutathion 0.92g and glutavene 3.74g are sequentially charged and agitated to limpidity, 6.90ml of sodium lactate is charged and agitated to limpidity, CaCl2 2.5ml of 0.1mol/L is charged and agitated to limpidity, and backup liquid and mother liquid are charged and agitated to limpidity. The pH is adjusted to 7.3-7.5, the osmotic pressure is adjusted to 320Osm/L, and the volume of double distilled water is set to 1000ml. The fluid is stored in low temperature of 4 DEG C.

The invention relates to the technical field of medical biology engineering, and provides an anti-human Oct 4 (octamer-binding protein 4) monoclonal antibody, recombinant protein for preparing the monoclonal antibody, a hybridoma cell strain secreting the monoclonal antibody as well as applications of the monoclonal antibody in western blot, expression of Oct 4 in immunohistochemical detection samples and preparation of prognosis evaluation preparations for liver cancer.

The invention discloses an extracting technology of dictyophora indusiata volva colloid polysaccharide, and belongs to the technical field of medical biology extraction. A freeze-thaw method is adopted for extracting colloid polysaccharide, dictyophora indusiata volva is taken to remove cortex to obtain intermediate dictyophora indusiata volva colloid, homogenizing is performed, the pH is adjusted, then, freezing is performed for 1-24 h under the temperature from subzero 20 DEG C to 0 DEG C, then, thorough dissolution is performed under the temperature of 20-80 DEG C, freezing and thawing are performed one to ten times repeatedly, and finally extraction, concentration and filtering are performed to obtain the dictyophora indusiata volva colloid polysaccharide. The advantage that the dictyophora indusiata colloid is high in water content is sufficiently utilized, no water needs to be added, the workload of follow-up concentration is lowered, efficiency is greatly improved, the extracting technology belongs to pure physical methods, no other chemical components are added, and the technology is safe and convenient to implement.

The invention discloses a preparation method of an anti-AIDS drug Azanavir intermediate and belongs to the technical field of medical biology. The method comprises the steps of adjusting the secondarystructure and codon preference of a gene by means of a full-gene synthesis approach, designing the length of a primer, synthesizing the primer, dissolving the obtained primer in double-distilled water, and adding the obtained solution into a following reaction system; amplifying the prepared PCR reaction system, performing gel cutting purification on DNA fragments obtained by PCR, and selecting amonoclonal sample for sequencing, wherein a correct DNA sequence is shown as SEQ ID NO.1 and named as Sst-1, and an amino acid sequence corresponding to the DNA sequence is shown as SEQ ID NO.2. Thepreparation method has the advantages that the reaction condition is mild, the requirement for equipment is low, high temperature or cooling is not required in a production process, the energy consumption is low, purification is convenient, single-enzyme catalysis is applied in the whole system, the ratio of substrate consumption to NAD consumption reaches 1,540:1, coenzyme circulation frequency is high, and the reaction conditions are mild.

The invention belongs to the technical field of medical biology, and relates to application of plasma metabolic markers in diagnosis or monitoring of HBV. The application of the plasma metabolic markers in the diagnosis or monitoring of the HBV aims to provide the application of the metabolic markers in blood in the preparation of reagents for diagnosing or monitoring a hepatitis B virus, wherein,the markers are one or more than one of Creatinine, L-Proline, L-Arginine, PC (P-16:0/20:4 (8Z, 11Z, 14Z, 17Z)), PE (18:2 (9Z, 12Z) / 18:1 (9Z), PC (o-16:1 (9Z) / 18:2 (9Z, 12Z), PC (P-16:0/18:1 (11Z), PE (18:2 (9Z, 12Z)/18:0), PE (P-16:0/22:4 (7Z, 10Z, 13Z, 16Z), PE (P-16:0/22:4 (7Z, 10Z, 13Z, 16Z), PE (P-18:0/18:2 (9Z, 12Z)), PE(18:0/18:1 (11Z), LysoPE (18:0/0:0), PE (16:0/18:1 (11Z), or PE (18:2 (9Z, 12Z)/16:0).

The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

The invention relates to the technical field of medical biology. Micro RNA-155 is micro ribonucleic acid (RNA) for regulating the maturation and natural immunoreaction of T cells and B cells. The invention provides a micro RNA-155-based plasmid for enhancing the immune effect of deoxyribonucleic acid (DNA) vaccine cells. A plasmid pcDNA 3.1-pre-miR-155 is obtained by inserting an expression sequence of a micro RNA-155 precursor molecule into a pcDNA-3.1 plasmid, and the micro RNA-155 precursor molecules can be expressed efficiently without influencing the expression capability of the co-transfected DNA vaccine. In an in-vivo test, the plasmid and the DNA vaccine are injected at the same time and have the capability of effectively introducing cellular immunoreaction, and such capability isrepresented by the increase of antigenically specific spleen IFN-gamma positive cells and enhancement of target killing capability of spleen CD8 positive cells. The plasmid of the invention can be added into the conventional DNA vaccine preparation and injected together so as to obviously promote the cellular immunoreaction induced by the DNA vaccine, and serves as a novel cell immune adjuvant.

The invention discloses a method for predicating gene age and disease susceptibility and a kit, and belongs to the technical field of medical biology and gene diagnosis. The method comprises the following steps: extracting cellular genome DNA of a host; testing polymorphic sites of genes (RTEL1 gene, ACYP2 gene, TERC gene, TERT gene, NAF1 gene, OBFC1 gene and ZNF208 gene) of a subject; and predicating the gene age and the disease susceptibility of the subject. According to the method, the correlation between the polymorphic sites of seven genes and senescence gene is described for the first time; the method can be applied to predication, auxiliary diagnosis and treatment of diseases caused by the senescence gene, and can be also applied to research and development of new drugs in order to guide the subject to start a healthy life.

The invention belongs to the technical field of medical biology, and particularly discloses a marker hsa - circRNA6448-14 for diagnosis and prognosis prediction of esophageal squamous cell carcinoma.The hsa - circRNA6448-14 is highly expressed in esophageal squamous cell carcinoma tissues, and is expressed in para-carcinoma normal tissues. By detecting the expression level of hsa - circRNA6448-14in tissues, the esophageal squamous cell carcinoma can be subjected to diagnosis and prognosis prediction. The invention provides a new approach for diagnosis and prognosis prediction of the esophageal squamous cell carcinoma, and provides a reference basis for clinicians to diagnose esophageal squamous cell carcinoma and analyze conditions of the esophageal squamous cell carcinoma.